ReviewDrug delivery and translational research2022
In vitro dissolution testing models of ocular implants for posterior segment drug delivery.
Review in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 24 citations in OpenAlex.
- Liposomal Drug Delivery in Ocular Therapy: Strategies for Enhancing Corneal Penetration and Bioavailability.Cells · 2026Review
- Critical Evaluation of Key Elements in Manufacturing Procedures and Testing Methodologies for Ocular Anti-Infective Thin Film Inserts.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Microenvironment-Responsive Drug Delivery Systems for Ocular Surface Diseases: Mechanisms, Applications, and Translational Challenges.Small science · 2026Review
- Injectable in-situ Forming Lipid Liquid Crystal for Long-acting Fluocinolone Release in Posterior Ocular Therapy: In-vitro and In-vivo Evaluations.Pharmaceutical research · 2026Article
- A sequential dual-drug delivery system for multi-target inhibition of subretinal fibrosis.Journal of nanobiotechnology · 2026Article
- Design of bifunctional RNA-binding compounds that can modulate siRNA hydrophobicity for deep penetration and gene silencing in the retina.Molecular therapy. Nucleic acids · 2025Article
- External stimuli-responsive drug delivery to the posterior segment of the eye.Drug delivery · 2025Review
- Comparison of In-Vitro and In-Vivo Drug Release of Dexamethasone/PLGA Intravitreal Implants Using Two In-Vitro Release Methods and a Rabbit Model.Molecular pharmaceutics · 2025Article
- Development of Practical Low-Volume Screening Method and Pharmacokinetic Simulation of Levofloxacin-Loaded Nanofiber Inserts for Sustained Ocular Therapy.Pharmaceutics · 2025Article
- An Update on Novel Drug Delivery Systems for the Management of Glaucoma.Pharmaceutics · 2025Review
- Dual-Phase Ocular Insert with Bromfenac-Loaded PLGA MPs in a PVA Matrix for Sustained Postoperative Anti-Inflammatory Delivery.Pharmaceutics · 2025Article
- Emerging trends in long-acting sustained drug delivery for glaucoma management.Drug delivery and translational research · 2025Review
- Nanotherapy for Neural Retinal Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Ocular Drug Delivery: Emerging Approaches and Advances.Pharmaceutics · 2025Review
- An exploration of the ocular mysteries linking nanoparticles to the patho-therapeutic effects against keratitis.Journal of nanobiotechnology · 2025Review
- A Transformative Wearable Corneal Microneedle Patch for Efficient Therapy of Ocular Injury and Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Envisioning the Future: Nanomicelles Revolutionizing Ocular Drug Delivery.Pharmaceutical nanotechnology · 2025Review
- Recent Advances in Smart Polymers-Based Therapeutics in Ophthalmology.International journal of nanomedicine · 2025Review
- Impact of mechanical engineering innovations in biomedical advancements.In vitro models · 2024Review
- Overview of Recent Advances in Nano-Based Ocular Drug Delivery.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The delivery of drugs to the posterior segment of the eye remains a tremendously difficult task. Prolonged treatment in conventional intravitreal therapy requires injections that are administered frequently due to the rapid clearance of the drug molecules. As an alternative, intraocular implants can offer drug release for long-term therapy. However, one of the several challenges in developing intraocular implants is selecting an appropriate in vitro dissolution testing model. In order to determine the efficacy of ocular implants in drug release, multiple in vitro test models were emerging. While these in vitro models may be used to analyse drug release profiles, the findings may not predict in vivo retinal drug exposure as this is influenced by metabolic and physiological factors. This review considers various types of in vitro test methods used to test drug release of ocular implants. Importantly, it discusses the challenges and factors that must be considered in the development and testing of the implants in an in vitro setup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.